Tirzepatide 5 mg approximates semaglutide 1 to 2 mg in clinical effect
Ill be honest: when I first saw GLP-1 skincare brands popping up, I thought it was smart marketing slapped on traditional anti-aging skincare that firms, lifts, and boosts collagen
Introduction The use of glucagon-like peptide-1 (GLP-1) receptor agonists, a class of drugs used to treat type 2 diabetes and obesity,12 has increased rapidly over the past decade owing to evidence of cardiovascular benefit in these populations.34567 This rapid uptake has been further driven by evidence showing that high dose semaglutide and the dual glucose dependent insulinotropic polypeptide-GLP-1 receptor agonist tirzepatide reduce weight by 10-20% in people with obesity with or without diabetes.28910 GLP-1 receptor agonists exert glycemic and weight lowering effects through mechanisms that include delayed gastric emptying, which could have important implications in the perioperative setting.111213 Recently, several published case reports have described pulmonary aspiration or retained gastric contents during elective procedures in patients using semaglutide despite adherence to appropriate fasting protocols.141516 In small observational studies, use of GLP-1 receptor agonists in patients undergoing upper gastrointestinal endoscopy or elective procedures requiring anesthesia was associated with retained gastric content compared with patients not using GLP-1 receptor agonists, which can increase the risk of pulmonary aspiration.17181920 In light of these safety signals and in an effort to minimize this potential risk, the American Society of Anesthesiologists published consensus based guidance to withhold GLP-1 receptor agonists in all patients for one dose before an elective procedure (one day for drugs administered daily and one week for those administered weekly).21 In response, concerns about the potential harms of discontinuing GLP-1 receptor agonists, particularly among people with diabetes, have been raised,22 with the American Gastroenterological Association issuing a clinical practice update urging that well designed studies should investigate the risk of pulmonary aspiration in GLP-1 receptor agonist users who require endoscopy.23 More recently, a multisociety statement was published emphasizing the lack of data to support stopping GLP-1 receptor agonists in all patients before elective endoscopy procedures.24 Additional evidence from robust pharmacoepidemiologic studies on the association between GLP-1 receptor agonist use and risk of pulmonary aspiration during upper endoscopy is needed
Clinician-Guided Weight Care Start with a health assessment for a licensed provider to review
As we age, our NAD levels decline
